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Cancer Centre, Northwood, United KingdomReceived Aug 28, 2020. Accepted for publication Nov 25, 2020.Purpose: Hypofractionated radiation therapy can be used to treat patients with muscle-invasive bladder cancer unable to have
radical therapy. Toxicity is a key concern, but adaptive plan-of the day (POD) image-guided radiation therapy delivery could
improve outcomes by minimizing the volume of normal tissue irradiated. The HYBRID trial assessed the multicenter imple-
mentation, safety, and efficacy of this strategy.
Methods: HYBRID is a Phase II randomized trial that was conducted at 14 UK hospitals. Patients with T2-T4aN0M0
muscle-invasive bladder cancer unsuitable for radical therapy received 36 Gy in 6 weekly fractions, randomized (1:1) to stan-
dard planning (SP) or adaptive planning (AP) using a minimization algorithm. For AP, a pretreatment cone beam computed
tomography (CT) was used to select the POD from 3 plans (small, medium, and large). Follow-up included standard cysto-
scopic, radiologic, and clinical assessments. The primary endpoint was nongenitourinary Common Terminology Criteria for
Adverse Events (CTCAE) grade  3 (G3) toxicity within 3 months of radiation therapy. A noncomparative single stage
design aimed to exclude 30% toxicity rate in each planning group in patients who received 1 fraction of radiation therapy.
Local control at 3-months (both groups combined) was a key secondary endpoint.
Results: Between April 15, 2014, and August 10, 2016, 65 patients were enrolled (SP, n Z 32; AP, n Z 33). The median
follow-up time was 38.8 months (interquartile range [IQR], 36.8-51.3). The median age was 85 years (IQR, 81-89); 68% of
participants (44 of 65) were male; and 98% of participants had grade 3 urothelial cancer. In 63 evaluable participants,
CTCAE G3 nongenitourinary toxicity rates were 6% (2 of 33; 95% confidence interval [CI], 0.7%-20.2%) for the AP group
and 13% (4 of 30; 95% CI, 3.8%-30.7%) for the SP group. Disease was present in 9/48 participants assessed at 3 months,
giving a local control rate of 81.3% (95% CI, 67.4%-91.1%).
Conclusions: POD adaptive radiation therapy was successfully implemented across multiple centers. Weekly ultrahypofrac-
tionated 36 Gy/6 fraction radiation therapy is safe and provides good local control rates in this older patient population. 
2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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Half of bladder cancer cases are diagnosed in patients aged
over 75 years, many of whom are not fit for major surgery
owing to their performance status and comorbidities or are
unable to attend hospital for 4 to 7 weeks for daily radical
radiation therapy.1-4
This population presents a management dilemma, with
unmet and potentially neglected clinical needs. A recent
UK Royal College of Radiologist audit showed that just
under 50% of patients with potentially curable T2 to T4
disease receive either no treatment or palliative radiation
therapy only,5 similar to reports elsewhere.6,7 Despite their
relatively poor performance status, many such patients have
a life expectancy of several years and, if left untreated, may
experience significant disease-related symptoms, such as
hematuria, increased urinary frequency, dysuria, pelvic
pain, urinary incontinence, and urinary obstruction.8
One option is to use ultrahypofractionated radiation
therapy, which was shown to be equivalent to daily palli-
ative radiation therapy treatment (35 Gy in 10 fractions) in
a multicenter, randomized, phase 3 trial in muscle invasive
bladder cancer (MRC BA09) that was conducted in the
1990s.8 However, the dose of 21 Gy in 3 fractions used in
MRC BA09 and given over 1 week is relatively low, and the
3-month local cystoscopic control was modest (14 of 37;
38%). Several centers have tested an alternative ultra-
hypofractionated schedule of 6 Gy per fraction weekly, for
a combined dose of 30 to 36 Gy over 5 to 6 weeks,9-11
which has a higher biological dose to the tumor than the
BA09 schedules.8 Data on the 6 Gy per fraction schedule
comes from retrospective reports and a single-center pro-
spective study.9-12
Bladder radiation therapy has traditionally used large
margins between the clinical target volume (CTV) and
planning target volume (PTV) to account for intrafraction
variation in position and shape. The extra radiation caused
by these large margins could add to toxicity, which presents
a concern in this frail population. Modern image-guided
adaptive radiation therapy protocols have been described to
account for these changes, with a view to improving clin-
ical outcomes. One option is to use a plan-of-the-day
approach, where a best-fit plan from a pre-prepared library
is used to more tightly conform to the target volume. This
could be particularly important in the context of ultra-
fractionation, where each fraction represents over 15% of
the total dose and missing a target or treating excessively
could have a greater proportionate impact than those during
conventional fractionation, where effects may be averaged
out. This makes ultrafractionation an excellent context in
which to test adaptive radiation therapy. Single-center
feasibility results of this approach in this population,
combined with ultrahypofractionated radiation therapy,
have been reported.12
To test these approaches on a multicenter basis, we
designed a non-comparative, randomized, phase 2 trial toassess the feasibility and clinic- and patient-reported out-
comes of weekly ultrahypofractionated radiation therapy
with and without adaptive radiation therapy in patients for
whom conventional radical treatment for bladder cancer
was unsuitable.Methods and Materials
Study design
HYBRID (CRUK/12/055) is a non-comparative, multi-
center randomized, phase 2 trial of ultrahypofractionated
bladder radiation therapy with or without image guided
adaptive planning in muscle-invasive bladder cancer from
14 National Health Service hospitals in the United
Kingdom. The aims were to assess the feasibility and safety
of delivering plan-of-the-day radiation therapy at multiple
National Health Service sites and to assess the overall
toxicity, patient-reported outcomes, and disease control
associated with ultrahypofractionated radiotherapy.13
Eligible patients were aged at least 18 years, had his-
tologically or cytologically confirmed bladder cancer
staged T2 to T4a N0 M0, were unable to receive radical
cystectomy or daily fractionated radiation therapy for any
reason, had an expected survival of >6 months, and had a
World Health Organization performance status of 0 to 3.
The key exclusion criteria were uncontrolled malig-
nancy in the past 2 years, prior pelvic radiation therapy or
major pelvic surgery, use of a urinary catheter, or any other
contra-indication to radiation therapy.
Participants were recruited by their clinical care teams in
the clinic and provided written informed consent before
enrollment. The trial was registered ISRCTN18815596,
approved by the London-Surrey Borders Research Ethics
Committee (13/LO/1350), sponsored by the Institute of
Cancer Research (ICR), and conducted in accordance with
the principles of good clinical practice. The ICR Clinical
Trials and Statistic Unit (ICR CTSU) coordinated the trial
and carried out central statistical data monitoring and all
analyses. The trial management group was overseen by
independent data monitoring and trial steering committees.
The full study protocol was published previously.13Randomization and masking
Treatment allocation was done centrally by ICR CTSU
within 4 to 6 weeks before patients were due to start ra-
diation therapy. Participants were assigned 1:1 between
standard and adaptive planning using a minimization al-
gorithm balanced for the radiation therapy treatment center
and incorporating a random element. Treatment allocation
was not masked.
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Radiation therapy planning details and the quality assur-
ance program are as described in Hafeez et al 202013 In
brief, all participants received 36 Gy in 6 fractions to the
bladder. Participants in the standard planning group
received radiation therapy using 1 plan throughout treat-
ment. Three treatment plans (small, medium, and large)
were generated for the adaptive planning (AP) group, with
pre-RT cone beam (CB) computed tomography (CT) used
to select the best fitting plan of the day for each fraction. A
quality assurance program accredited individuals for plan
selection. A single expert reviewer, (S.H.), blinded to out-
comes, assessed concordance between online and offline
plan selection retrospectively.
The CTVencompassed the visible tumor, whole bladder,
and any area of extravesical spread. CTV to PTVexpansion
margins for SP and AP are given in Table E1. An example
of derived PTVs is given in Fig. E6A. The margins for the
adaptive planning are as derived from modeling work and
validated in a subsequent single-center, phase 2
study.12,14,15
Comorbidity was assessed at baseline using the Charlson
Comorbidity Index.16 A clinician assessment of toxicity
was conducted weekly during treatment using the National
Cancer Institute’s Common Terminology Criteria for
Adverse Events (CTCAE) v4.0, with full blood count, urea,
and electrolytes assessed at fractions 2, 4, and 6. CTCAE
toxicity was subsequently assessed at 4 weeks and 3, 6, 12,
and 24 months after the final radiation therapy fraction.
Radiation Therapy Oncology Group (RTOG) toxicity was
assessed by clinicians at 6, 12, and 24 months. A cysto-
scopic assessment of response was conducted at 3, 6, 12,
and 24 months if possible, with urine cytology and a CT
scan of the pelvis if the cystoscopic assessment was not
possible. Participants were followed-up annually from 2
years for disease-related endpoints.
Patient-reported outcomes (PRO) were captured using
the modified Inflammatory Bowel Disease Questionnaire
(IBDQ; bowel function), the King’s Health Questionnaire
(KHQ; urologic function), and the EuroQol 5-dimensions,
5-levels questionnaire (EQ5D; overall health status).
Questionnaires were completed by participants on paper
before radiation therapy, at fraction 6 and 3 and 6 months
after completing radiation therapy.Outcomes
The primary endpoint was nongenitourinary (non-GU)
CTCAE G3 toxicity occurring within the first 3 months of
radiation therapy completion. Secondary endpoints
included the proportion of adaptive fractions delivered (ie,
whether the small or large plan was selected; AP group
only); appropriate identification of fractions requiringadaptive planning and selection of an appropriate plan;
acute toxicity; late toxicity (up to 2 years); control rate of
presenting symptoms; PROs assessed using the modified
IBDQ, EQ5D, and KHQ; local disease control at 3 months;
time to local disease progression; time to invasive local
disease progression; and overall survival. Time to bladder
cancer death was an exploratory endpoint.
Acute adverse events were categorized according to
whether they emerged or worsened during treatment and
their relationship to treatment. In this report, “adverse
event” refers to an event that was not present at baseline or
was reported at a higher grade than at baseline and
“toxicity” refers to the subset of adverse events that were
categorized as treatment related.
The categorization of relatedness of primary endpoint
events to study treatment was reviewed by the independent
data monitoring committee, which was blinded to the
planning method.
Statistical analysis
The study was designed to rule out an acute G3 non-GU
AP toxicity rate of 30%, assuming an expected rate of
10%.12 In each planning group, an A’Hern single-stage
exact design (p0 Z 0.70; p1 Z 0.9; a Z 0.05; b Z
0$2), required at least 24/28 evaluable participants to be
G3 non-GU toxicity free for the hypofractionated plan of
the day to be considered safe for radiation therapy. A 10%
nonevaluable rate was accounted for in the target sample
size of 62 patients.
Prospective power calculations were performed for a
number of key secondary outcomes. With 62 participants,
there was sufficient power to rule out a G3 overall acute
toxicity rate of hypofractionated radiation therapy of 40%
or more (a Z 0.05; b Z 0.2) and a 3-month control rate
(allowing for 25% nonevaluable patients) of less than 40%
(a Z 0.05; b Z 0.13). It was estimated that approximately
50% of fractions in the AP group would be adapted.12 To
assess the clinical utility of online correction, a threshold of
25% of all fractions or 1 fraction/patient requiring adaption
was set. In the AP group, if true agreement between the
online and offline protocols for plan selection was 85%,
plan selection outcomes for 139 fractions would allow us to
demonstrate agreement for >75% of fractions with 90%
power (under a single-stage exact binomial approach).
There were no formal early stopping rules for efficacy or
toxicity. However, an initial independent safety review took
place when the 3-month data were available for 5 patients
(who had received at least 3 fractions of radiation therapy)
in each planning group.
For the primary endpoint, the evaluable population
was all randomized patients who received at least 1
fraction of radiation therapy. This and other safety end-
points were analyzed according to the planning method
received. Proportions are reported with 95% 2-sided
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mary and other key endpoints with prespecified threshold
criteria, 90% 2-sided CIs are also provided (consistent
with a 95% 1-sided design). Late toxicity is summarized
by frequencies and proportions at each time point and
overall assessments are shown by planning group and
presented graphically. The time to the first instance of
G2 late toxicity was analyzed using competing risk
methodology. Symptom control (graded the same, worse,
or better than baseline) was assessed in patients with
symptoms reported at baseline and is presented graphi-
cally for each planning group.
PRO data were analyzed in accordance with the
relevant scoring manuals,17-19 with 3 months as the time
point of primary interest. The modified IBDQ consists of
32 questions each, graded from 1 (worst possible
symptom) to 7 (symptom absent or not changed since
before radiation therapy). IBDQ total subscale scores
were calculated by summing together all individual
scores for patients with answers to all questions in that
subscale.17 The KHQ is comprised of 3 parts with 21
items. For parts 1 and 2, items are scored between
0 (best) and 100 (worst) with a 4-point rating system,
except for 1 item in part 1 (general health perceptions)
that has a 5-point rating system.18 Part 3 is considered as
a single item and is scored from 0 (best) to 27 (worst).
The EQ5D consists of 5 domains, each graded from 1
(worst possible symptom) to 5 (symptom absent) except
for 1 domain (pain) that is graded from 1 (worst possible
symptom) to 4 (symptom absent).19 Changes in the mean
scores were calculated from baseline to each posttreat-
ment time point and were compared between randomized
groups at 3 months using the analysis of covariance
model, adjusting for baseline score. For the IBDQ and
EQ5D, higher scores indicate better health; for the KHQ,
lower scores reflect better health.
The local control rate at 3 months is presented for both
planning groups combined. To consider the impact of early
deaths and missed 3-month assessments, a sensitivity
analysis was conducted and assumed: (1) bladder
cancererelated deaths before the 3-month assessment were
evidence of failure of local control; and (2) there was dis-
ease control at 3 months if the 3-month assessment was
missing but the patient was reported as free of disease at a
later time point with no intervening treatment.
Time-to-event endpoints, where the interest is in onco-
logical outcomes of hypofractionation, are analyzed in the
intention-to-treat population, summarized by Kaplan-Meier
curves and presented for randomized groups combined. For
overall survival, alive patients were censored on the date
they were last seen. For other endpoints, patients with no
events were censored on the date of last assessment of
disease status (ie, date of last cystoscopy, biopsy, urine
cytology, or CT scan). Patients who died before any follow-
up were censored at the date of death.
Analyses were conducted using STATA version 15.0
based on a snapshot of data taken on June 10, 2019.Results
Patient characteristics
Between April 15, 2014, and August 10, 2016, 65 partici-
pants were recruited from 14 UK centers (Table E2). Of
these, 32 patients were randomized to the SP group and 33
to the AP group (Fig. 1). All participants received radiation
therapy given in accordance with their allocated planning
method.
Patient characteristics are summarized in Table 1. The
median age of participants was 85 years (interquartile range
[IQR], 81-89), 68% (44 of 65) were male, and 98% had
grade 3 urothelial carcinoma histology. A complete trans-
urethral resection of the bladder tumor had been per-
formed in 31%. The median age-adjusted Charlson co-
morbidity index score was 7, and scores ranged from 5 to
11 (IQR, 6-8).Treatment delivery
Of the 65 patients, 58 (89%) completed 6 fractions of
treatment, with the remaining 7 patients stopping early
(Fig. 1).
In the AP group, 28 of 33 patients (85%) received at
least 1 fraction using a plan other than the medium plan
(95% CI, 68%-95%; Fig. E1), either using a small plan only
throughout treatment (2 of 33 [6%]) or using 2 or more
plans during treatment (2 plans, 22 of 33 [67%]; 3 plans, 4
of 33 [12%]). Overall, the number of fractions using a plan
other than medium exceeded our target of 25%, with 76 of
193 fractions (39%; 95% CI, 32%-47%) delivered using a
small plan (46 of 193; 24%) or a large plan (30 of 193;
16%).
Of 193 pretreatment CB CTs, 117 (60.6%) were avail-
able for central retrospective review, with a 78% (91 of
117) concordance rate between online plan selection and
central review. In cases of discordance, the online plan
selection was larger than the reviewer’s selection in 20 of
26 cases (77%; Table E3). The small plan was selected by
the offline reviewer in 39 of 117 (33%) fractions, compared
with 28 of 117 (24%) online selections.Acute toxicity
Toxicity rates were lower than the prespecified threshold in
both groups. CTCAE G3 non-GU toxicities were reported
in 2 out of 33 participants (6%; 90% CI, 1.1%-17.9%; 95%
CI, 0.7%-20.2%) in the AP group and 4 out of 30 (13%;
90% CI, 4.7%-28.0%; 95% CI, 3.8%-30.7%) in the SP
group (Table 2). In each group, G3 gastrointestinal tox-
icities were reported for 1 patient (included in non-GU
toxicities).
The G3 GU toxicities were more frequent than those
that were non-GU, affecting 3 out of 33 (9%; 95% CI,
32 allocated to standard 
planning
Due to receive 6 Gy 
fractions of RT 
delivered weekly 
(36 Gy over 6 weeks)
33 allocated to adaptive 
planning
*2 pts non-evaluable and 
died of bladder cancer 
with acute toxicity 
received to week 6
6 BC-related deaths
2 deaths due to 
concomitant illnesses
3 BC-related deaths 
4 deaths due to 
concomitant illnesses
30 patients 33 patients
All received SP
28 received 6f (36 Gy)
†3 received 5f (30 Gy)
†1 received 2f (12 Gy)
All received AP
30 received 6f (36 Gy)
†2 received 5f (30 Gy)









12 month follow-up 18 patients 21 patients 
4 BC-related deaths
3 BC-related deaths 
2 deaths due to 
concomitant illnesses
9 patients alive and in 
follow-up
9 patients alive and in 
follow-up
8 BC-related deaths 
4 deaths due to 
concomitant illnesses
5 BC-related deaths 





65 patients with pT2-T4a N0 M0
bladder carcinoma unsuitable for 
standard daily radiotherapy
Fig. 1. CONSORT diagram. )Classed as nonevaluable by Trial Steering Committee due to bladder cancer death before
3-month assessment or insufficient follow-up receipt. yStopped treatment early due to toxicity. zStopped treatment early due
to concomitant illness. Abbreviation: APZ adaptive planning; BC Z bladder cancer; CONSORT Z Consolidated Standards
of Reporting Trials; f Z fractions; ITT Z intention to treat; RT Z radiation therapy; SP Z standard planning.
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Table 1 Baseline characteristics by allocated planning method
Standard planning, n Z 32 Adaptive planning, n Z 33 Total, n Z 65




1.7 (1.2-2.1) 1.4 (1.0-2.1) 1.6 (1.1-2.1)
Sex
Male 24 (75%) 20 (61%) 44 (68%)
Female 8 (25%) 13 (39%) 21 (32%)
Extent of resection
Biopsy 10 (31%) 10 (30%) 20 (31%)
Partial resection 10 (31%) 13 (39%) 23 (35%)
Full resection 11 (34%) 9 (27%) 20 (31%)
Unknown/missing 1 (3%) 1 (3%) 2 (3%)
Multiple tumors
Yes 6 (19%) 7 (21%) 13 (20%)
No 26 (81%) 26 (79%) 52 (80%)
Histologic tumor type
Urothelial 31 (97%) 32 (97%) 63 (97%)
Nonurothelial 1 (3%) 1 (3%) 2 (3%)
Grade
G2 1 (3%) 0 (0%) 1 (2%)
G3 31 (97%) 33 (100%) 64 (98%)
CIS present
Yes 9 (28%) 11 (33%) 20 (31%)
No 22 (69%) 22 (67%) 44 (68%)
Unknown/missing 1 (3%) 0 (0%) 1 (2%)
Clinical stage
T2 24 (75%) 21 (64%) 45 (69%)
T3a 1 (3%) 5 (15%) 6 (9%)
T3b 5 (16%) 5 (15%) 10 (15%)
T4a 2 (6%) 2 (6%) 4 (6%)
NM stage
N0/M0 32 (100%) 33 (100%) 65 (100%)
Age adjusted Charlson Comorbidity index score
5 1 (3%) 0 (0%) 1 (2%)
6 14 (44%) 13 (39%) 27 (42%)
7 11 (34%) 5 (15%) 16 (25%)
8 4 (13%) 6 (18%) 10 (15%)
9 2 (6%) 8 (24%) 10 (15%)
10 0 (0%) 0 (0%) 0 (0%)
11 0 (0%) 1 (3%) 1 (2%)
Abbreviation: CIS Z carcinoma in situ; IQR Z interquartile range; NM stage Z nodal/metastatic stage.
Data are shown as n (%) or median (IQR).
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(17%; 95% CI, 5.8%-35.8%) in the SP group (Table 2).
The overall incidence of G3 toxicity was lower than
the predefined threshold rate of 40% (12 of 63; 19%; 90%
CI, 11.4%-29.0%; 95% CI, 10.2%-30.9%). The distribution
of overall, GU, and non-GU toxicities are shown in Fig. 2.
No grade 4 or 5 toxicities were reported.
The equivalent data for all acute adverse events,
regardless of relatedness to treatment, are shown in Table 2.
Overall, 31.7% (20 out of 63) of patients had an acute G3
acute adverse event.Late toxicity
Late toxicity is summarized in Fig. 2 and Fig. E2.
Overall rates of late toxicity were low. In patients with
at least 6 months of follow-up, 2 of 21 patients (9.5%)
in the SP group and 3 of 26 (11.5%) in the AP group
reported grade 2 or greater RTOG toxicity with a
single episode of RTOG grade 3 toxicity reported in an
AP patient (cystitis recorded at the 24-month follow-
up). The time to first G2 toxicity is shown in
Fig. E3.
Table 2 Acute  grade 3 toxicities and adverse events
Standard planning, n Z 30 Adaptive planning, n Z 33 Overall, n Z 63
n % (95% CI) n % (95% CI) n % (95% CI)
Toxicity
Non-GU* 4 13.3% (3.8-30.7) 2 6.1% (0.7-20.2) 6 9.5% (3.6-19.6)
GIy 1 3.3 % (0.1-17.2) 1 3.0% (0.1-15.8) 2 3.2% (0.4-11.0)
GUz 5 17.2 % (5.8-35.8) 3 9.1% (1.9-24.3) 8 12.9% (5.7-23.9)
Any 7 23.3% (9.9-42.3) 5 15.2% (5.1-31.9) 12 19.0% (10.2-30.9)
Adverse event
Non-GU 10 33.3% (17.3-52.8) 7 21.2% (9.0-38.9) 17 27.0% (16.6-39.7)
GIy 1 3.3% (0.1-17.2) 2 6.1% (0.7-20.2) 3 4.8% (1.0-13.3)
GUz 8 27.6% (12.7-47.2) 3 9.1% (1.9-24.3) 11 17.7% (9.2-29.5)
Any 10 33.3% (17.3-52.8) 10 30.3% (15.6-48.7) 20 31.7% (20.6-44.7)
Abbreviation: GI Z gastrointestinal; GU Z genitourinary; SP Z standard planning.
Adverse event refers to an event that was not present at baseline or was reported at a higher grade than at baseline, and toxicity refers to the subset of
adverse events that were categorized as treatment related.
* This row shows the primary endpoint.
y GI is a subset of non-GU.
z One SP patient with GU had data that was not assessable. The patient was counted in the denominator.
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The rate of control at 3 months of urinary symptoms is
shown in Fig. E4 for each planning method separately.
Hematuria, incontinence, and cystitis were improved in the
majority of patients compared to baseline (hematuria, 12 of
16 [75%]; incontinence, 8 of 14 [57%]; cystitis, 11 of 19
[58%]). Frequency symptoms, though the same or better in
most patients, only improved for the minority (nocturia, 8
of 39 [21%]; frequency/urgency, 12 of 36 [33%]).
Patient-reported outcomes
There was no statistically significant difference between the
2 planning groups for IBDQ bowel-related symptoms or for
any other IBDQ symptoms, nor for the EQ5D health score
or KHQ domain scores, at 3 months (Tables E4, E5 and E6;
Fig. 3). Of note, the IBDQ demonstrated a worsening in
bowel and systemic symptoms at Week 6 in the SP group
which was not seen in the AP group (Table E4). This
improved over the following 6 months and returned to
baseline in both groups. The total IBDQ score, EQ5D
health status, and KHQ symptom severity score over time
are shown by patient in Fig. E5.
Disease control and survival outcomes
At 3 months, 48 participants had their disease status
assessed. Local disease was controlled in 39 out of 48
participants (81.3%; 90% CI, 69.6%-89.9%; 95% CI,
67.4%-91.1%). The rates of local control were 17 out of 23
(74%) in the SP group and 22 out of 25 (88%) in the AP
group. A sensitivity analysis suggested at least 41 out of 61
patients (67.2%; 90% CI, 56.0%-77.1%; 95% CI, 54.0%-
78.7%) had evidence of local control, thus, consistent withthe main analysis, ruling out a 3-month control rate of less
than 40%.
At a median of 38.8 months follow-up, 33 patients had
reported 36 recurrences: 21 in the bladder (ie, local recur-
rence), 4 in the pelvic nodes, and a further 9 at distant sites
(2 nodal and 7 at other distant sites). The proportion of
patients free of local recurrence at 1 year was 71.7% (95%
CI, 55.9%-82.6%) and the proportion free of invasive local
recurrence was 85.5% (95% CI, 70.1%-93.3%; Fig. 4).
There have been 47 deaths, of which 31 are due to
bladder cancer. The median survival time was 18.9 months,
with 61.5% (95% CI, 48.6%-72.1%) alive at 1 year and
46.2% (95% CI, 33.8%-57.7%) alive at 2 years.Discussion
We set out to investigate whether the use of adaptive
hypofractionated radiation therapy to a dose of 36 Gy in 6
fractions, in the context of a multicenter, prospective, ran-
domized trial, could be an option for patients with
advanced localized bladder cancer who were unable to
receive standard radical treatment options. The study met
its primary acute toxicity endpoint, ruling out excessive
non-GU and overall toxicity and demonstrating that local
control could be achieved in over 80% of participants at 3
months with this ultrahypofractionated weekly regimen. In
ultrahypofractionated protocols, each fraction makes up a
substantial proportion of the total treatment, so accuracy of
delivery is important because it is difficult to compensate
for even a single missed day. In this context we have, to the
best of our knowledge, completed the first randomized trial
of adaptive plan-of-the-day radiation therapy in bladder
cancer. We have shown that a substantial portion of radia-
tion therapy fractions may benefit from the use of a plan
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Fig. 2. Stacked bar chart of the worst-grade acute toxicity, acute adverse event, late toxicity, and RTOG. Worst-grade (A)
acute CTCAE toxicity, (B) acute CTCAE adverse event, (C) late CTCAE toxicity, and (D) RTOG. Adverse event refers to an
event that was not present at baseline or was reported at a higher grade than at baseline, and toxicity refers to the subset of
adverse events that were categorized as treatment related. Abbreviation: CTCAE Z Common Terminology Criteria for
Adverse Events; GI Z gastrointestinal; GU Z genitourinary; RTOG Z Radiation Therapy Oncology Group.
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elderly, frail population.
Treating this group of patients who, by virtue of age,
performance status, or comorbidity are not fit for radical
treatment but have potentially curable disease, is one of the
large challenges facing clinicians treating muscle-invasive
bladder cancer. This group of patients represents a sub-
stantial and understudied subset of patients. A recent UK
study suggested that 47% of patients (representing 2519
patients per year) with T2 to T4 N0 bladder cancer are not
receiving either radical radiation therapy or surgery.20
A remarkable feature of this trial was that it included a
group of patients with a median age of 85 and significant
comorbidity, as indicated by the Charlson Comorbidity
index scores. The ability to complete this randomized study
with good quality data, including data on local control and
patient-reported outcomes, and with excellent adherence to
allocated treatment shows that with an appropriate, flexible
design it is possible to involve this patient population inresearch protocols, and they are willing to participate and
be enrolled in trials.
Efficacy results from this phase 2 study are promising. A
3-month local control rate of over 80%; a 1-year invasive,
local recurrenceefree rate of 86%; and a median survival
time of 18.9 months with over 40% of patients surviving 2
years posttreatment suggests that this schedule of 36 Gy in
6 fractions can be effective at controlling disease in patients
with bladder cancer. Although on the face of it the survival
figures are inferior to those reported in trials of chemo-
radiotherapy,21 this treatment does still provide a reason-
able chance of long-term survival and compares favorably
with the 55% 1-year survival rate in patients receiving
palliative treatments and the 32% survival rate with no
treatment reported in the Royal College of Radiologist
audit.5 In general, these results support the findings of the
single-center, prospective, phase 2 study that was the pilot
for this trial.12 In the pilot study, which included some




















































































































Fig. 3. Mean change from baseline for the total IBDQ score, EQ5D health status and KHQ symptom severity score.
Change from baseline in (A) IBDQ total score, (B) EQ5D health status score, and (C) KHQ Symptom severity measures
score. Error bars represent 95% CIs. Negative numbers represent a decrease in quality of life and positive numbers represent
an increase in quality of life for IBDQ and EQ5D. For KHQ, negative numbers represent an increase in quality of life and
positive numbers represent a decrease in quality of life. Abbreviation: AP Z adaptive planning, bl Z baseline; CI Z
confidence interval; EQ5D Z EuroQol 5-dimensions, 5-levels questionnaire; IBDQ Z Inflammatory Bowel Disease
Questionnaire; KHQ Z King’s Health Questionnaire; SP Z standard planning.
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Fig. 4. Kaplan-Meier plots of time to event. Time to (A) local recurrence, (B) local invasive recurrence, (C) overall
survival, and (D) bladder cancer death. Number of events and number censored are presented as cumulative in the extended
risk table. Shaded area represents 95% CI. Abbreviation: CI Z confidence interval.
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1-year survival rate of 63% and a 2-year survival rate of
around 35%.12 Similar results have been reported for a
number of retrospective studies22 and suggest the regimen
of 36 Gy in 6 fractions may be superior to the hypo-
fractionated schedule of 21 Gy in 3 fractions used in the
MRC-BA09 trial, which reported a 38% local control rate
in the small number of patients assessed.8
Although patients did experience a degree of acute
toxicity, our trial met preset thresholds for acute tolera-
bility, and late toxicity seemed uncommon. Thus, this study
suggests that the regime of 36 Gy in 6 fractions weekly is a
regime that can achieve local control in a significant pro-
portion of patients and be tolerated even by an unfit pop-
ulation, making this a real treatment option for this patient
population.
This study was also designed to develop preliminary
clinical data on the value of an adaptive plan-of-the-day
strategy. A significant body of evidence has accumulated
showing that the changes in shape and position of the
bladder through a treatment course can lead to a geographicmiss despite the use of large CTV to PTV margins, which
may contribute to increased toxicity in their own right. The
advent of pre-treatment soft-tissue imaging has been used
to develop a number of strategies to improve target
coverage and reduce target margins. Foremost of these is
the use of a plan of the day, where 1 of a set of predesigned
plans of varying sizes is chosen. Previous work with plans
of the day has resulted in target coverage higher than his-
torical reports with reduction of the average PTV volume
by 28% to 42%.14,23-26
Our results here broadly support previous results, with
39% of treatments using either a small or large plan and
most patients using either an adapted plan throughout or 2
or more of the 3 plans. This exceeds our minimum futility
rate of 25% of treatments using an adapted plan and, as the
medium plan used in this trial is smaller than a standard
plan, 84% of treatments were treated with a plan smaller
than normally used. This reflects reports from other studies
of plan-of-the-day radiation therapy. Vestergaard et al24
reported roughly equal usage of small, medium, and large
plans, resulting in a roughly 30% reduction in average PTV
Huddart et al. International Journal of Radiation Oncology  Biology  Physics12volume, whereas Foroudi et al23 used small or large plans
for around 50% of fractions, resulting in a 29% reduction in
the high-dose radiation volume.
It is encouraging that this study was deliverable in an
environment where the technique was unfamiliar to most
hospitals before their participation. As previously reported,
all sites undertook a quality assurance program, including a
training package on plan selection for which staff members
needed to attain a preset level of concordance with an
expert-defined selection to gain approval to select plans for
the purposes of trial treatment.27,28 A central review shows
this training was relatively effective, with 78% concor-
dance, but in most discrepant cases the expert reviewer
selected a smaller plan, evidencing the need for ongoing
peer support and feedback in the implementation of this
technique.
This study did have a number of limitations. Because it
was a moderate-sized, noncomparative, phase 2 study,
limited statements can be made about the benefits of
adaptive radiation therapy compared with standard radia-
tion therapy or of the 36 Gy/6 fraction schedule compared
with other treatments. The data are also limited by early
deaths and dropouts, meaning that not all patients could be
assessed for toxicity, local control, and patient-reported
outcomes. Despite these limitations, it is encouraging that
the number of grade 3 to 4 non-GU and GU toxicity and
adverse events are numerically lower in the adaptive arm.
Additionally, fewer patients stopped radiation therapy early
because of adverse events, and the higher immediate
bowel-related quality of life is encouraging.
The trends in favor of improved outcomes for
adaptive treatments should logically lead to a formal
comparative study to confirm the degree of the clinical
benefit from adaptive therapy, either in this patient
group or in studies of patients receiving daily frac-
tionated radiation therapy.Conclusions
Adaptive ultrahypofractionated radiation therapy is deliv-
erable with modest toxicity in an elderly, unfit population of
patients, while achieving local control for the majority. It
represents a new option for care in this patient population.References
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